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Abstract Catheter-related thrombosis (CRT) is a serious
complication in hematological patients, but the risk factors
for its occurrence are not well established. The study
objectives were to estimate the incidence of CRT and to
identify the risk factors for developing CRT in hematolog-
ical patients. In a prospective setting, 104 consecutive
patients with 200 insertions of central venous catheters were
enrolled into the study. The patients were screened for CRT
by compression Doppler ultrasound every 10–14 days.
Additionally, ultrasonography was performed in the case of
clinical symptoms suggesting CRT. Over the course of
6,098 catheter days of follow-up, the incidence of CRT was
13.5 %. In 18/27 cases (66.6 %), radiological evidence of
CRT was preceded by clinical symptoms. However, in 9/27
(33.3 %), CRT was clinically asymptomatic. The median
times to symptomatic and asymptomatic CRT were 17
(range 1–49) and 8 (range 1–16) catheter days, respectively.
In univariate analysis, the risk factors for CRT were exit-site
infection (ESI) (P \ 0.001), two or more prior chemother-
apy lines (P = 0.015), catheter-related blood stream infec-
tion (P \ 0.001), and Coagulase-negative staphylococci
infection (P = 0.002). In multivariate analysis, ESI (OR 5.0;
95 % CI 1.6–6.3; P = 0.006) and two or more prior che-
motherapy lines (OR 3.57; 95 % CI 1.27–10.11; P = 0.015)
remained significantly associated with the risk of CRT. The
results of our study provide information regarding the
characteristic features of the patients who are at high risk of
thrombosis, for whom Doppler ultrasound screening should
be considered.
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infection  Blood stream infection  Doppler
ultrasound
Introduction
Central venous catheters (CVCs) are frequently used in
hematological patients in order to administer chemotherapy
and other infusates, as well as blood and stem cell products.
In addition, CVCs may also be used for blood sampling.
Reported complications consist of mechanically related
ones, CVC-related infections, and thrombosis. The patho-
genetic mechanisms of catheter-related thrombosis (CRT)
include the intravascular foreign surface, obstruction of the
venous flow, and trauma to the venous wall. Although the
pathogenesis of CRT is multifactorial, venous endothelial
damage appears to play the most important role. This
damage may be the result of mechanical irritation by the
line [1], or may arise as a consequence of the use of certain
drugs, e.g., cytostatics, antibiotics, and of parenteral
nutrition. Moreover, there is accumulating evidence that
CRT and CVC-related infections are not separate entities,
but seem to have a bidirectional relationship [2–7].
Previous studies of CRT have mainly been based on
retrospective analyses of oncological and intensive care
unit patients. There is a little data available relating to
hematological patients. These patients differ from others
with respect to more severe and prolonged thrombocyto-
penia and leucopenia, as well as to abnormalities of plasma
coagulation. Hematological patients are usually treated by
the implantation of short-term non-tunneled percutaneous
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catheters inserted via the internal jugular, subclavian, or
femoral veins.
There are discrepancies in the literature relating to CRT.
Many risk factors have been postulated, including the type
of catheter, insertion site, CVC tip localization, previous
CRT, method of treatment, CVC-related infection, difficul-
ties during insertion, and inherited thrombophilia [8–13].
According to the literature, CRT is clinically silent in two-
thirds of all CRT cases. In these cases, the clot does not close
the vein completely [14]. Among hematological patients,
clinically asymptomatic CRT is diagnosed in 1.5–34 % of
them [8, 15, 16]. In these patients, CRT is usually diagnosed
after 4–20 days, on average within 11 days [2]. The clinical
symptoms of CRT vary widely and consist of swelling or
pain, numbness, erythema of the extremity, phlegmasia, and
venous distension. Symptomatic CRT occurs in 1.2–13 % of
hematological patients [2, 3, 16–21].
The diagnosis of CRT by venography is considered as
the ‘‘gold standard,’’ but it has some important limitations.
This invasive method requires the administration of con-
trast media and radiography and is associated with the risk
of serious complications. For these reasons, venography
has been largely replaced by compression Doppler ultra-
sound in many centers for the diagnosis of CRT. The
advantages of this method include its wide availability,
noninvasiveness, and relatively short duration. The sensi-
tivity of Doppler ultrasound ranges from 78 to 100 % and
the specificity from 82 to 100 % [22].
In our study, the aims were to estimate the incidence of
CRT and to identify the risk factors for developing this
condition in hematological patients.
Materials and methods
Study population
The study was performed in the Department of Hematol-
ogy, Poznan University of Medical Sciences.
A registry of patients undergoing CVC insertion for
therapy was initiated in March 2008 and completed in
March 2010. Consecutive patients who underwent CVC
positioning were eligible to this study, and the only one
exclusion criterion was the lack of consent to participate.
The study was approved by the Ethics Committee of the
University. Informed consent was obtained from all patients.
Procedures of catheter insertion and maintenance
Catheter insertions were performed in a surgery by a staff
physician under standard sterile conditions—sterile gloves
and small drape. Before the procedure, the patients took an
antiseptic shower. At the time of catheter insertion, the
insertion site was cleaned with 1 % alcohol-based povi-
done-iodine solution.
The same type of central venous catheter, a 16-cm-long,
3-lumen polyurethane catheter impregnated with chlorhexi-
dine/silver sulfadiazine (Arrow) was used for every patient.
The decision on the choice of insertion site was taken by
the responsible physician and was mainly based on per-
sonal preferences and the patient’s underlying character-
istics. In patients with a history of previous CRT, the CVC
was inserted in another vein or into the same vein after
exclusion of CRT.
CVC insertion was performed under local anesthesia by
the percutaneous technique, guided by anatomic landmarks.
In those patients in whom the CVC had been inserted in
the internal jugular or subclavian veins, location of the tip of
the catheter tip in the superior vena cava or right atrium was
confirmed by standard chest radiography (Cosmos Siemens).
Neither antibiotic prophylaxis nor any thromboprophy-
laxis was administered. Maintenance procedures were
performed by trained hematological nurses and included
the replacement of sterile gauze dressings at least every
48 h, or earlier after contamination or detachment. Where
transparent polyurethane dressings (Tegaderm Film 3 M)
were need, these changes were made not less frequently
than weekly. During the exchange, the CVC site was dis-
infected by Skinsept preparation (alcohol-based and
hydrogen peroxide solution). Moreover, all catheter’s
lumens were flushed with 0.9 % NaCl daily.
Follow-up period
The observation time covered the period from insertion to
removal of the catheter. The catheter was removed at the
end of hospitalization, or earlier in cases of mechanical
obstruction, and in some cases of CRT and/or catheter-
related blood stream infection (CRBSI) and/or exit-site
infection (ESI).
Doppler ultrasound
Ultrasound with Doppler and color imaging (GE Voluson
730 Pro) was performed every 10–14 days and additionally
if any clinical symptoms suggesting CRT were noted.
Every evaluation was carried out by the same radiolo-
gist. CRT was diagnosed after finding a thrombus with
partial or total occlusion of the vessel. In cases of internal
jugular or femoral vein thrombosis, additional confirmation
was provided by a positive compression test.
Microbiology surveillance
The patients were screened for CVC-related infections.
Two entities were distinguished: ESI and CRBSI. The
772 Page 2 of 7 Med Oncol (2014) 31:772
123
CVC-related infections were defined according to the
Clinical Practice Guidelines for the Diagnosis and Man-
agement of Intravascular Catheter-Related Infections: 2009
Update by the Infectious Diseases Society of America
(IDSA) [23].
At each episode of fever onset (body temperature
[38.2 C) or other symptoms of infection, paired quali-
tative blood cultures were performed from both the catheter
and a peripheral vein. The blood samples were injected into
BacT/Alert FN and BacT/Alert FA culture media. Analyses
were performed using a computerized system for moni-
toring blood cultures (BacT/Alert 3D Bio-Merieux). The
differential time to positivity (DTP) was evaluated. DTP
was defined according to the IDSA (23) as a growth in a
blood culture obtained through a catheter hub and detected
by an automated blood culture system, at least 2 h earlier
than a culture of simultaneously drawn peripheral blood of
equal volume.
Additionally, swab cultures (Eurotubo Collection Swab,
Delta Lab) were taken in the presence of clinical signs of
ESI with exudation. Catheter distal tip culture was per-
formed routinely.
The identification and drug sensitivity of cultured
microorganisms were made by the Vitek 2 Compact system
(Bio-Merieux) with standard interpretation of susceptibility
according to the Clinical and Laboratory Standards Insti-
tute (CLSI). For some pathogens, sensitivity was estimated
using the E-test.
Laboratory data
Platelet cell count (hematology analyzer Abbott Cell Dyn
3700) was evaluated in patients who developed CRT. The
plasma D-Dimers concentration (ACL Elite Pro, commer-
cial test kit Instrumentation Laboratory/Comesa) was ana-
lyzed in all patients.
Statistical analysis
The Pearson chi-square statistical test and Fisher–Free-
man–Halton 2-sided test were used to compare the general
characteristics of patients with and without CRT. Univar-
iate analysis of CRT for each potential risk factor was
performed using logistic regression. Exposures for which
the P value was \0.10 in the univariate analysis were
submitted to a multivariate conditional logistic regression
model. Backward stepwise regression procedures were
used to develop the final multivariate model. A P value
\0.05 was considered as significant. Odds ratios (ORs) and
95 % CIs (confidence intervals) were calculated on the
basis of the final model.
All statistical analyses were performed using Statistica
for Windows (StatSoft, Inc. 2001).
Results
Patients and CVC positioning
A total of 200 cases of CVC positioning in 104 patients
with a median age of 45 years (range 18–76) were enrolled
in the study.
The main patient and catheter characteristics are pre-
sented in Table 1.
The overall median follow-up time was 27 days (range
4–183), for a total of 6,098 catheter days.
The median follow-up of patients who developed CRT
was 22 days (range 12–49). In 17/27 cases, the catheter
was removed after confirming CRT. All the patients with
CRT were treated with enoxaparin, with the therapeutic






Acute myeloblastic leukemia 80 (40)
Acute lymphoblastic leukemia 37 (18.5)
B cell chronic lymphocytic leukemia 10 (5)
Non-Hodgkin lymphoma 44 (22)
Hodgkin lymphoma 17 (8.5)
Other hematological disorders 4 (2)
Disease status
Complete/partial remission 148 (74)







Prolonged chemotherapy infusion ([12 h) 86 (43)
Cisplatin-based polychemotherapy 41 (20.5)
Catheter placement
Right internal jugular vein 109 (54.5)
Left internal jugular vein 41 (20.5)
Right subclavian vein 17 (8.5)
Left subclavian vein 7 (3.5)
Right femoral vein 23 (11.5)
Left femoral vein 3 (1.5)
Tip localization
Superior vena cava 154 (77)
Superior vena cava/right atrium 12 (6)
Right atrium 7 (3.5)
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dose adjusted to the platelet count and the clinical symp-
toms of thrombocytopenia.
CRT incidence
Of the total of 200 insertions, CRT was confirmed in 27
(13.5 %). Radiological evidence of CRT was preceded by
clinical symptoms in 18 of these 27 cases (66.6 %).
However, in 9 of these 27 patients (33 %) and in 4.5 % of
the total group of 200 insertions, CRT was clinically silent.
The median times to symptomatic CRT and clinically
asymptomatic CRT were 17 catheter days (range 1–49) and 8
catheter days (range 1–16), respectively. Thrombosis was
confirmed within 15 days from catheter placement in 11
cases, between 15 and 30 days in 14 cases, and beyond
30 days in 2 cases. CRT was associated with CVC-related
infections in 13/27 cases (48.1 %). Thirteen cases of ESI
were present, and additionally, 6 cases met the criteria of
CRBSI. Based on the Pearson chi-square test, we analyzed
incidence of CRT in the different subgroups of patients. The
incidence rate of CRT differed significantly between groups
of patients stratified by a number of prior chemotherapy
lines, CRBSI, exit-site infection, and infection by Coagulase-
negative staphylococci (CoNS) (Table 2). In contrast, no
association was found between the incidence rate of CRT
and age of patient, prior CRT, underlying hematological
disorder, time of cytostatic infusion ([12 vs. B12 h), type of
chemotherapy (cisplatin-based chemotherapy vs. others), tip
localization, D-dimer concentration, or catheter insertion site.
Risk factors
Based on univariate logistic regression analysis, we iden-
tified four risk factors of CRT (Table 3).
Multiple logistic regression analysis revealed two inde-
pendent risk factors of CRT: exit-site infection (OR 5.01;
95 % CI 1.6–6.3; P = 0.006) and two or more prior che-
motherapy lines (OR 3.57; 95 % CI 1.27–10.11; P = 0.015).
Discussion
CRT is a serious complication in hematological patients.
Few studies relating to the incidence of CRT and associ-
ated risk factors in patients treated for hematological dis-
orders have been published. Therefore, our aims were to
evaluate this incidence and to identify risk factors for CRT
in patients hospitalized in our center.
In all the studies reported in the literature, CRT was
investigated in patients in whom the catheters were inserted
via different types of vascular access port. The catheters that
were of either the tunneled or non-tunneled types were
impregnated or unimpregnated, placed in peripheral or
central veins, and had different numbers of lumen. Our study
was carried out on a large group of patients with the same
type of CVC 3 lumen polyurethane catheter impregnated
with chlorhexidine/silver sulfadiazine (Arrow).
We confirmed the incidence of CRT in 27 catheterization
cases, representing a prevalence of 13.5 %. In almost half
the cases, CRT was associated with CVC-related infections.
In two-thirds of the cases, the radiological signs were pre-
ceded by clinical symptoms. In the remainder, CRT was
diagnosed based by Doppler ultrasound screening. Our
results are not consistent with data available in the literature,
and van Rooden et al. [24] found that episodes of asymp-
tomatic CRT occur in two-thirds of all CRT. The difference
may originate from the fact that they performed Doppler
ultrasound every 7 days, compared to the 10–14 days in our
investigation. As a result, the incidence of asymptomatic
CRT is probably underestimated in our study.
We were not able to predict the risk of symptomatic
CRT on the basis of asymptomatic CRT, due to the small
number of patients affected and the fact that in most cases,
the treatment was implemented immediately after detecting
the thrombosis. According to the literature, clinically silent
CRT seems to be relevant, because it increases the risk of
developing symptomatic thrombosis sevenfold, compared
with negative Doppler ultrasound findings [24]. The
guidelines for screening Doppler ultrasound testing in
hematological patients have not yet been established.
Based on the fact that a significant percentage of clinically
silent CRT evolves into symptomatic CRT, we believe
Table 2 Incidence of venous catheter-related thrombosis in the
subgroups of patients
Groups CRT incidence rate P
Number of prior chemotherapy lines
1 versus 2 or more 11.1 versus 27.6 % 0.033
CRBSI
No versus yes 11.6 versus 30.0 % 0.009
Exit-site infection
No versus yes 8.6 versus 18.0 % \0.001
Infection by CoNS
No versus yes 10.7 versus 34.7 % 0.001
CRT catheter-related thrombosis, CRBSI catheter-related blood
stream infection, CoNS Coagulase-negative staphylococci
Table 3 Univariate analysis of risk factors of catheter-related
thrombosis
Risk factor OR (95 % CI) P
Two or more prior chemotherapy lines 3.22 (1.24–8.36) 0.015
Exit-site infection 6.05 (2.51–14.5) \0.001
CRBSI 3.83 (1.29–11.3) 0.001
CoNS infection 4.43 (1.65–11.9) 0.002
OR odds ratio, CI confidence interval, CoNS coagulase-negative
staphylococci, CRBSI catheter-related blood stream infection
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strongly that Doppler ultrasound screening should be
considered in this group of patients. In our study, the
median time from the last normal Doppler ultrasound to the
Doppler ultrasound with CRT was 8 days (range 1–16).
Based on these data, Doppler ultrasound screening for CRT
every seven days seems to be advisable, especially in
patients with a high risk of developing CRT.
In our group of 200 catheter insertions, the median time
to diagnosis of CRT (both symptomatic and asymptomatic)
was 17 days. Noteworthy is the fact that the longest time to
CRT after catheter insertion, beyond 30 days occurred in
only two cases. These data are consistent with reports in
the literature [2]. The treatment of hematological patients is
often complicated by grade 3–4 thrombocytopenia, which
might be expected to reduce the risk of CRT. However, this
presumption is not reflected in data in the literature [8]. In
the presence of inflammation, inflammatory mediators
stimulate the formation of young and more thrombogenic
platelets. Furthermore, inflammatory mediators release
extremely large multimers of von Willebrand factor from
the endothelium, which stimulates the formation of large
platelet thrombi [25]. In our CRT patients, the median
platelet count (PLT) was 45 (range 10–592) G/L. These
findings are justified in the context of described mecha-
nisms of increased thrombotic risk during infection, irre-
spective of concomitant thrombocytopenia.
In our study, we analyzed many parameters as potential
risk factors. We found no difference in the incidence of
CRT in the female group compared to the male group.
With regard to age, our patients were divided patients into
4 groups: those of 18–29, 30–39, 40–49, and C50 years,
respectively. The patients in the oldest age group suffered
from many of the co-morbidities predisposing to throm-
bosis. Despite this, none of the groups showed an increased
risk of CRT. These data are consistent with previous
reports in the literature [1, 8]. In our study, there was not
also a significant risk of CRT recurrence. We found two
reports in the literature with the same conclusion [1, 8]. We
also studied the different CVC insertion sites as a potential
risk factor of CRT. We did not find an increased risk of
CRT in any of the catheter placements such as the right
internal jugular, the left internal jugular, the right sub-
clavian, the left subclavian, the right femoral, or the left
femoral vein. We also compared the incidence of CRT
after placement in the internal jugular veins versus to
subclavian or femoral veins and also compared the internal
jugular and subclavian veins versus femoral veins. There
were no differences. We also found no difference in the
incidence of CRT with catheter placement on the right side
of the body versus the left side. In summary, we did not
find any correlation between the risk of CRT and the
catheter placement site. There are reports that locating the
catheter tip in the brachio-cephalic vein or distal part of the
superior vena cava poses a greater risk of CRT than
locating the tip in the proximal part of the superior vena
cava or right atrium results in an increased risk of CRT [9,
10]. The results of our study do not confirm this finding.
Among the other potential risk factors, we also analyzed
underlying hematological disorders, but we did not find an
increased incidence of CRT in any group of patients. In the
available literature, there is one report concerning a pedi-
atric group which claimed ALL diagnosis as a risk factor
for thrombosis [26], but our findings do not support this
observation.
Due to the fact that endothelial cell damage triggers the
initiation of thrombotic processes, the use of intensive
chemotherapy may be a risk factor for thrombotic com-
plications. In our study, we analyzed the relationship
between CRT and cisplatin-based regimens. Cisplatin, one
of the inorganic compounds of platinum, works indepen-
dently of the phase of the cell cycle, inhibits DNA syn-
thesis to form intra- and interchain DNA connections, and
is characterized by a long half-life (20–30 h). In our group
of patients, cisplatin in a dose of 25 mg/m2 was adminis-
tered as a continuous infusion for 4 days as a part of
ESHAP (etoposide, cisplatin, cytarabine, methylpredniso-
lone) chemotherapy. There are data in the literature indi-
cating an increased risk of deep vein thrombosis,
pulmonary embolism, and ischemic stroke in cancer
patients treated with cisplatin-based chemotherapy [27].
However, we were unable to find any published reports
about the risks of CRT after cisplatin, and in our study, we
did not find any increased risk of CRT in those of our
patients treated with cisplatin-based polychemotherapy.
Similarly, the results of our study do not confirm the
influence of prolonged infusions ([12 h) of other cytotoxic
drugs (cytarabine, ifosfamide, cisplatin, methotrexate) on
the risk of CRT.
Treatment with subsequent lines of chemotherapy, other
angiotoxic medications, and repeated CVC placements can
all damage the endothelium. We therefore analyzed the risk
of CRT depending on the number of prior chemotherapy
lines. Comparing the incidence of CRT in patients who
underwent two or more chemotherapy lines with the expe-
rience of patients previously untreated or treated with only
one line of chemotherapy, we found a statistically significant
increased incidence of CRT in the first group (P = 0.033).
Univariate analysis using logistic regression confirmed this
correlation between previous therapy with two or more
chemotherapy lines and CRT (P = 0.015). Multivariate
analysis confirmed treatment with more than 2 prior che-
motherapy lines is an independent risk factor for CRT,
increasing the risk of CRT more than threefold. Our results
may be important from a practical point of view, suggesting
the need for increased clinical supervision and Doppler
ultrasound screening in heavily pretreated patients. So far,
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we are aware this relationship has not been reported
previously.
The D-dimer concentration in plasma was another lab-
oratory parameter analyzed in our study as a risk factor of
CRT. We did not find any correlation between an elevated
D-dimer concentration and the incidence of CRT. Because
of the multiplicity of causes increasing the D-dimer con-
centration, the results obtained are not surprising, but
clearly illustrate the fact that this concentration has no
value as a diagnostic test of CRT in hematological patients.
Many studies have shown a strong relationship between
the pathogenesis of infectious and thrombotic processes [2,
5, 7]. A major factor connecting CRT and CVC-related
infections is the formation of a fibrin sheath around the
catheter and inside the catheter lumen. CVC-related thrombi
consist of many proteins, such as fibrin, fibronectin, colla-
gen, and laminin. Microorganisms, especially Staphylococ-
cus aureus and Staphylococcus epidermidis, easily adhere to
the catheter and produce coagulase enzymes enhancing the
thrombotic process. This relationship was analyzed in our
study. We confirmed the presence of CRBSI in 10 % cases.
Literature data on the incidence of CRBSI in hematological
patients varies widely, ranging from 0 to 20.8 %. These
differences arise from the different definitions used for
CRBSI. In our study, 76.1 % of CRBSI cases were the result
of staphylococcal infections. The most common pathogenic
factor for CRBSI was Staphylococcus epidermidis MRS.
This bacterium belongs to the coagulase-negative staphylo-
cocci and forms a part of the skin flora. Our findings relating
to both the species of pathogen and the incidence of infec-
tion are in line with the literature data [21]. Concomitant
CRT was confirmed in 33.3 % of our CRBSI cases. A
preliminary analysis showed an increased incidence of CRT
in patients meeting the criteria for CRBSI (P = 0.009).
Analysis by a logistic univariate regression model confirmed
the association between CRBSI and CRT (P \ 0.001), but
multivariate analysis did not show that CRBSI is an inde-
pendent factor of CRT.
Due to the fact that ESI is usually the first manifestation
of a catheter-related infection, we analyzed its relationship
with CRT. Clinical symptoms of ESI were observed in 36
cases, with purulent drainage in 12 of them. The micro-
organisms cultured from purulent drainage belonged to
staphylococci in more than 80 % cases. We demonstrated
an increased incidence of CRT in patients with ESI
(P \ 0.001) that was observed in one-third of the ESI
cases. Multivariate analysis identified ESI as an indepen-
dent risk factor, increasing the risk of the CRT fivefold. On
the basis of our results, we conclude that the risk of CRT
correlates with the incidence of CVC-related infections,
and preventive strategies should therefore include the
effective prevention and treatment of CVC-related
infections.
In summary, our results indicate that those hematolog-
ical patients with CVC who present exit-site infection, or
who were heavily pretreated, are at high risk of developing
CRT. We therefore recommend the use of Doppler
screening as an aid in the early diagnosis of CRT.
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